NEXTCELL PHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.28 SEK | -0.78% |
|
+1.99% | -51.33% |
Valuation
| Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 62.94 | 106.1 | 246.9 | 498.5 | 218.3 | 123.8 |
| Enterprise Value (EV) 1 | 59.82 | 85.93 | 224.9 | 359.3 | 121.2 | 73.74 |
| P/E ratio | -4.49 x | -3.2 x | -11.9 x | -18 x | -6.32 x | -3.11 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 96 x | 54.1 x | 59.7 x | 112 x | 35 x | 8.87 x |
| EV / Revenue | 91.3 x | 43.8 x | 54.4 x | 80.7 x | 19.5 x | 5.28 x |
| EV / EBITDA | -4.35 x | -4.07 x | -13 x | -14.7 x | -3.51 x | -1.82 x |
| EV / FCF | -7.2 x | -5.93 x | -17.1 x | -20.7 x | -4.27 x | -2.19 x |
| FCF Yield | -13.9% | -16.9% | -5.84% | -4.82% | -23.4% | -45.8% |
| Price to Book | 12.5 x | 4.62 x | 9.42 x | 3.32 x | 1.89 x | 1.63 x |
| Nbr of stocks (in thousands) | 8,505 | 19,144 | 23,398 | 34,380 | 34,380 | 34,380 |
| Reference price 2 | 7.400 | 5.540 | 10.55 | 14.50 | 6.350 | 3.600 |
| Announcement Date | 11/9/18 | 11/14/19 | 11/3/20 | 11/3/21 | 11/3/22 | 11/9/23 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.6554 | 1.961 | 4.137 | 4.454 | 6.229 | 13.96 |
| EBITDA 1 | -13.75 | -21.11 | -17.33 | -24.48 | -34.57 | -40.55 |
| EBIT 1 | -14.05 | -21.46 | -17.73 | -24.91 | -35.02 | -41 |
| Operating Margin | -2,143.19% | -1,094.19% | -428.58% | -559.33% | -562.26% | -293.81% |
| Earnings before Tax (EBT) 1 | -14.03 | -21.45 | -17.68 | -24.56 | -34.55 | -39.81 |
| Net income 1 | -14.03 | -21.45 | -17.68 | -24.56 | -34.55 | -39.81 |
| Net margin | -2,140.98% | -1,093.89% | -427.35% | -551.34% | -554.72% | -285.28% |
| EPS 2 | -1.650 | -1.733 | -0.8901 | -0.8075 | -1.005 | -1.158 |
| Free Cash Flow 1 | -8.307 | -14.5 | -13.12 | -17.32 | -28.38 | -33.74 |
| FCF margin | -1,267.42% | -739.21% | -317.24% | -388.89% | -455.63% | -241.78% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/9/18 | 11/14/19 | 11/3/20 | 11/3/21 | 11/3/22 | 11/9/23 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 3.12 | 20.1 | 22 | 139 | 97.1 | 50 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -8.31 | -14.5 | -13.1 | -17.3 | -28.4 | -33.7 |
| ROE (net income / shareholders' equity) | -116% | -153% | -71.9% | -27.9% | -26% | -41.6% |
| ROA (Net income/ Total Assets) | -58.3% | -76.1% | -39.2% | -16.8% | -15.6% | -24% |
| Assets 1 | 24.09 | 28.17 | 45.06 | 146.2 | 221.2 | 165.8 |
| Book Value Per Share 2 | 0.5900 | 1.200 | 1.120 | 4.370 | 3.360 | 2.200 |
| Cash Flow per Share 2 | 0.3700 | 1.050 | 0.9400 | 4.050 | 2.820 | 1.460 |
| Capex | - | 0.4 | 0.79 | 0.73 | 7.59 | 4.1 |
| Capex / Sales | - | 20.22% | 19.03% | 16.3% | 121.85% | 29.37% |
| Announcement Date | 11/9/18 | 11/14/19 | 11/3/20 | 11/3/21 | 11/3/22 | 11/9/23 |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -51.33% | 4.14M | |
| +33.63% | 50.85B | |
| -0.09% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +11.18% | 26.11B | |
| -21.95% | 19.13B | |
| +8.61% | 13.05B | |
| +28.31% | 12.16B | |
| +24.73% | 12.08B |
- Stock Market
- Equities
- NXTCL Stock
- Financials NextCell Pharma AB